TAME Trial
TAME Trial

The Targeting Aging with Metformin Trial



As seen in a Ron Howard-directed National Geographic special and featured in TEDMED, JAMA, WIRED, The New York Times, The Wall Street Journal, The Washington Post, CNN.com, The TODAY Show, and more:

The Targeting Aging with Metformin (TAME) Trial, managed by AFAR, shows promise for revolutionizing healthy aging and the way age-related diseases are treated. 

Explore this high profile, high-impact project through these FAQS

What is the TAME Trial?

Targeting Aging with Metformin (TAME) is a novel clinical trial, that will test whether the drug metformin, a widely-used treatment for type 2 diabetes, can delay the onset of age-related diseases and conditions including cancer, cardiovascular disease and Alzheimer’s disease.

Why Metformin? Why Now?
Metformin is an FDA-approved first-line drug for the treatment of type 2 diabetes, used successfully for over 60 years with an outstanding safety record. Studies in the biology of aging have shown that metformin can delay aging in animals. These findings point to the likelihood that metformin may influence fundamental aging factors that underlie multiple age-related conditions in humans.

Has the FDA approved this trial?
We MUST do the trial first which will open the door to FDA approval of aging as an indicator, as well as to the development of new drugs that will target aging. (Metformin has been approved by the FDA for over 50 years.)

How can TAME impact other diseases and aging in general? 
By targeting fundamental aging factors, TAME researchers hope to delay or prevent the onset of all age-related diseases simultaneously, rather than treat each one individually as they arise and accumulate.

Headlines have alluded that Metformin will help us live to be 120 years old? Is this true?
This is false. The goal is to add health to our years.  Reputable news stories on TAME can be found here and here or visit our media highlights page.  

What is AFAR’s role?
AFAR has supported the planning process of TAME, led by AFAR Deputy Scientific Director Nir Barzilai, MD. AFAR's Scientific Director Steven Austad, PhD and board members James Kirkland, MD, PhD, and S. Jay Olshansky, PhD also have been instrumental in building the case for TAME.  AFAR is helping manage the process to build financial and instutional support to lauch the TAME clinical trials.

What can the public do to help or support TAME and aging research? 
Follow AFARorg on Facebook and Twitter for updates and to show your support in numbers.

What’s next?
Your support will help move the TAME trial ahead, and in doing so, pave the way for the Food and Drug Administration (FDA) to consider aging a modifiable condition and an official “indication” for which treatments can be developed and approved.This could lead to increased funding and research, and expanded and better drug development to target aging factors, not just specific age-related diseases and conditions. TAME can open the door to ongoing research and other drug developments that will help us all live healthier, longer.



More on TAME